Results 101 to 110 of about 697 (188)

Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohort. [PDF]

BMC Cancer
Wenzel M, Filzmayer M, Siech C, Le QC, Lauer B, Theissen L, Hoeh B, Heinzer H, Graefen M, Steuber T, Kriegmair M, Chun FK, Mandel P.   +12 more
europepmc   +1 more source

Arylsulfonylation of 5, 5-Disubstituted 2-Thiohydantoins

YAKUGAKU ZASSHI, 1970
A, Kobayashi, S, Umemoto, A, Kagemoto
openaire   +3 more sources

Apalutamide-induced life-threatening dermatologic toxicity: Clinical histopathological correlations and salvage therapies in four cases: Case report series. [PDF]

Medicine (Baltimore)
Li Y, Cao Y, Wei L, Zhao J, Tao M, Zhao X.   +5 more
europepmc   +1 more source

Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. [PDF]

Future Oncol
La Cerda J, Thorley J, Sieber P, Cookson MS, Flanders SC, Gatoulis SC, Shore ND.   +6 more
europepmc   +1 more source

A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer. [PDF]

Front Immunol
Tasaki Y, Naiki T, Mimura Y, Sugiyama Y, Tomita M, Morikawa T, Nagai T, Unno R, Etani T, Hamamoto S, Umemoto Y, Yasui T, Furukawa-Hibi Y.   +12 more
europepmc   +1 more source

[3+2]-Cycloaddition of azomethine ylides to 5-methylidene-3-aryl-2-сhalcogen-imidazolones: access to dispiro indolinone-pyrrolidine-imidazolones. [PDF]

R Soc Open Sci, 2022
Kukushkin ME, Kondratieva AA, Karpov NA, Shybanov DE, Tafeenko VA, Roznyatovsky VA, Grishin YK, Moiseeva AA, Zyk NV, Beloglazkina EK.   +9 more
europepmc   +1 more source

Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors. [PDF]

Cancer
Liu MA, Raghunathan R, Runcie K, Wooster M, Wang S, Wright JD, Wei AZ, Stein M, Hershman DL.   +8 more
europepmc   +1 more source

The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53-MDM2 Modulation. [PDF]

Pharmaceuticals (Basel)
Girgis AS, Zhao Y, Nkosi A, Ismail NSM, Bekheit MS, Aboshouk DR, Aziz MN, Youssef MA, Panda SS.   +8 more
europepmc   +1 more source

Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study. [PDF]

Int J Urol
Suzuki K, Khan N, Taguchi T, Hattori K, Chen G, Ghadessi M, Constantinovici N, Quintero V, Suzuki H.   +8 more
europepmc   +1 more source

The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer. [PDF]

Future Oncol
Shore ND, George DJ, Spratt DE, De La Cerda J.   +3 more
europepmc   +1 more source